Life sciences R&D portfolio strategy
Integrating platform, pipeline, and partnership strategy in AI-enabled drug discovery
Focusing scarce capital on the programs and capabilities that create the most value
Situation
An AI-enabled drug discovery company was building a proprietary platform alongside an internal pipeline, pharma partnerships, and a platform services business. Each competed for the same capital and scientific talent, while investors and partners expected visible progress toward value inflection points.
Complication
Drug development remained a long game, even as the platform improved timelines and probability of success. Wholly owned programs offered the most value but consumed the most cash, while partnered programs brought funding at the cost of upside. Decisions on the platform, pipeline, partnerships, and services were made separately, with no common logic for allocating capital. There was a real risk of spreading resources too thin to build a lasting advantage.
Resolution
We worked closely with the CEO and executive team to build an integrated strategy across the platform, pipeline, partnerships, and services. This included assessing platform capabilities and gaps, selecting focus therapeutic areas and indications, and prioritizing programs on unmet need, scientific merit, competition, commercial potential, and contribution to the platform. We also used build-buy-partner analysis to define an acquisition agenda tied to specific value drivers, and focused business development on the partners and services that best fit the platform strategy.
Impact
- Created a comprehensive strategy leveraging a detailed capabilities assessment to drive innovation and value creation
- Aligned leadership on a common framework for platform, pipeline, and partnership decisions
- Built a focused portfolio of internal and partnered programs in priority therapeutic areas
- Completed multiple acquisitions to fill key capability gaps, including human-relevant disease models, computational molecular modeling, and wet lab capabilities
- Secured a major pharma partnership that funded and validated the platform
